RLAYRelay Therapeutics, Inc.

1. Aug 6, 2026Relay Therapeutics, Inc. (the “Company”) previously entered into a common stock sales agreement (the “Original Sales Agreement”), dated August 6, 2024, with TD Securities (USA) LLC (“TD Cowen” or the “Sales Agent”), relating to shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) …Material agreement entered · Form 8-K
2. Jun 9, 2026On June 9, 2026, Relay Therapeutics, Inc. (the “Company”) filed a Certificate of Second Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the number of authorized shares of …Charter/bylaw amendment or fiscal-year change · Form 8-K
3. May 21, 2026On May 20, 2026, Relay Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Jefferies LLC and TD Securities (USA) LLC, as representatives of the several underwriters listed on Schedule 1 thereto (collectively, the “Underwriters”), relating to an underwritten …Material agreement entered · Form 8-K
4. May 19, 2026On May 19, 2026, the Company announced initial clinical data from the Phase 2 ReInspire trial of zovegalisib in vascular anomalies.Regulation FD disclosure · Form 8-K
5. May 5, 2026Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates.Earnings release · press release
6. Apr 27, 2026On April 27, 2026, the Company announced clinical data from the zovegalisib, fulvestrant and atirmociclib triplet combination arm of the Phase 1/2 ReDiscover trial as well as the Company's plans to move zovegalisib plus atirmociclib into Phase 3 development for 1L patients with PI3Kα-mutated, HR+/HER2- metastatic …Regulation FD disclosure · Form 8-K
7. Mar 16, 2026On March 16, 2026, the Company announced data from the Phase 1/2 ReDiscover trial of zovegalisib in combination with fulvestrant at the 400mg BID fed dose, which is the recommended Phase 3 dose, at the European Society for Medical Oncology Targeted Anticancer Therapies Congress 2026.Regulation FD disclosure · Form 8-K
8. Feb 26, 2026Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones.Earnings release · press release
9. Feb 3, 2026On February 3, 2026, the Company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to zovegalisib (RLY-2608) in combination with fulvestrant for the treatment of adults with PIK3CA mutant hormone receptor positive, human epidermal growth factor receptor 2-negative …Regulation FD disclosure · Form 8-K
10. Nov 6, 2025On November 4, 2025, upon the recommendation of its Nominating and Corporate Governance Committee, the Board of Directors (the "Board") of the Company increased the number of members of the Board from seven to nine and appointed each of Lonnel Coats and Habib Dable as members of the Board, effective as of November 4 …Earnings release · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.